Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 11/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 9/20 | 0.42 |
| ▸ | NMT1 | P30419 | 2/20 | 0.39 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.38 |
| ▸ | CDC42BPB | Q9Y5S2 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | GFER | P55789 | 1/20 | 0.36 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21638128 | 0.91 | SMN1; SMN2 (0.47) | ADORA2AADORA1NMT1CRHR1ROCK2 | |
| SCHEMBL21638127 | 0.91 | SMN1; SMN2 (0.47) | ADORA2AADORA1NMT1CRHR1ROCK2 | |
| SCHEMBL20296612 | 0.89 | ADORA2A (0.36) | ADORA2AADORA1NPC1GAAMAPT | |
| SCHEMBL18344115 | 0.84 | NPY5R (0.38) | NMT1NPC1GAAMAPTRAB9A | |
| SCHEMBL20296756 | 0.84 | ADORA2A (0.42) | ADORA2AADORA1CRHR1SMN1; SMN2KDM4E | |
| SCHEMBL23965741 | 0.83 | RAB9A (0.46) | ADORA2AADORA1NMT1NPC1MAPT | |
| SCHEMBL18344033 | 0.76 | MAP4K4 (0.46) | NPC1GAAMAPTRAB9ASMN1; SMN2 | |
| SCHEMBL18344137 | 0.75 | NPC1 (0.43) | NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL18344186 | 0.75 | RAB9A (0.49) | NPC1GAAMAPTRAB9ASMN1; SMN2 | |
| SCHEMBL5091471 | 0.74 | ADORA2A (0.46) | ADORA2AADORA1NMT1CRHR1ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107743483-B | NADPH oxidase 4 inhibitors | 埃科特莱茵药品有限公司 | 2022-01-28 | — | — | CN | claimed |
| US-11136317-B2 | NADPH oxidase 4 inhibitors | ACTELION PHARMACEUTICALS LTD (CH) | 2021-10-05 | — | — | US | claimed |
| EP-3310767-B1 | 2,5-DISUBSTITUTED BENZOXAZOLE AND BENZOTHIAZOLE COMPOUNDS AS NADPH OXIDASE 4 INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2020-07-22 | — | — | EP | claimed |
| US-20200165235-A1 | NADPH OXIDASE 4 INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2020-05-28 | — | — | US | claimed |
| US-20180179194-A1 | NADPH OXIDASE 4 INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2018-06-28 | — | — | US | claimed |
| EP-3310767-A1 | NADPH OXIDASE 4 INHIBITORS | Actelion Pharmaceuticals Ltd. (CH) | 2018-04-25 | — | — | EP | claimed |
| WO-2016207785-A1 | NADPH OXIDASE 4 INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2016-12-29 | — | — | WO | claimed |
| CN-107743483-B | NADPH oxidase 4 inhibitors | 埃科特莱茵药品有限公司 | 2022-01-28 | — | — | CN | disclosed |
| US-20210395238-A1 | NADPH OXIDASE 4 INHIBITORS | ACTELTION PHARMACEUTICALS LTD (CH) | 2021-12-23 | — | — | US | disclosed |
| US-11136317-B2 | NADPH oxidase 4 inhibitors | ACTELION PHARMACEUTICALS LTD (CH) | 2021-10-05 | — | — | US | disclosed |
| EP-3310767-B1 | 2,5-DISUBSTITUTED BENZOXAZOLE AND BENZOTHIAZOLE COMPOUNDS AS NADPH OXIDASE 4 INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2020-07-22 | — | — | EP | disclosed |
| US-20200165235-A1 | NADPH OXIDASE 4 INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2020-05-28 | — | — | US | disclosed |
| US-10584118-B2 | NADPH oxidase 4 inhibitors | ACTELION PHARMACEUTICALS LTD (CH) | 2020-03-10 | — | — | US | disclosed |
| US-20180179194-A1 | NADPH OXIDASE 4 INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2018-06-28 | — | — | US | disclosed |
| EP-3310767-A1 | NADPH OXIDASE 4 INHIBITORS | Actelion Pharmaceuticals Ltd. (CH) | 2018-04-25 | — | — | EP | disclosed |
| WO-2016207785-A1 | NADPH OXIDASE 4 INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2016-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10584118-B2 | NADPH oxidase 4 inhibitors | NOX4, NOX1, CYBB | ADORA2A 3834/4885ADORA1 3540/4885NMT1 1795/4885 |
| US-20200165235-A1 | NADPH OXIDASE 4 INHIBITORS | NOX4, NOX1, CYBB | ADORA2A 3834/4885ADORA1 3540/4885NMT1 1795/4885 |
| US-11136317-B2 | NADPH oxidase 4 inhibitors | NOX4, NOX1, CYBB | ADORA2A 3834/4885ADORA1 3540/4885NMT1 1795/4885 |
| US-20180179194-A1 | NADPH OXIDASE 4 INHIBITORS | NOX4, NOX1, CYBB | ADORA2A 3834/4885ADORA1 3540/4885NMT1 1795/4885 |
| US-20210395238-A1 | NADPH OXIDASE 4 INHIBITORS | NOX4, NOX1, CYBB | ADORA2A 3834/4885ADORA1 3540/4885NMT1 1795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.